Business Wire

SMITHS-DETECTION

10.10.2019 08:02:08 CEST | Business Wire | Press release

Share
Smiths Detection Showcases Biometric Checkpoint Solution at inter airport Europe 2019

Global threat detection and security technologies company, Smiths Detection is showcasing for the first time an integrated checkpoint solution at inter airport Europe 2019, which harnesses biometric technology to enable risk-based screening practices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005541/en/

With air passenger growth predicted to double by 2037, the aviation industry will be challenged to support this capacity growth whilst providing operational efficiencies and meeting shifting passenger expectations of the airport experience.1 To cope with this growth, biometric technology is being increasingly adopted at airport Border Control gates, bag drop and boarding gates.

As leaders in providing checkpoint solutions to airports across the world, Smiths Detection has partnered with experts in the field of biometry to, for the first time, create a proof of concept which integrates biometric identity management solutions with class-leading screening solutions. Inter airport delegates are invited to experience the biometric capable checkpoint in action – which also employs Smiths Detection’s advanced CT scanner, HI-SCAN 6040 CTiX , the iCMORE Weapons automatic object recognition capability and the advanced tray return system, iLane.evo .

Biometrics is the ‘unique identifier’ for passengers, and through integration of biometrics directly into the checkpoint, passengers can be matched with their trays to enable real-time risk-based screening. Risk-based screening is designed to increase operational efficiency and effectiveness through continual risk assessments relevant to the individual passenger journey, resulting in shorter and easier journeys for passengers.

Through passenger and tray identification, new data insights can be gathered to inform decision making at airports - based on flights, airlines or destinations. Matching passengers with trays also enables the sharing of screening results with transit or arrival airports, and the combination of hold baggage and checkpoint screening results.

“At Smiths Detection, we’re dedicated to delivering a seamless passenger journey and we are very excited to be driving biometric checkpoint technology forward in a rapidly developing marketplace,” said Smiths Detection Vice President Europe, Africa and Marketing Tony Tielen . “As a trusted partner to airports across the world, we are working with the aviation industry to deliver risk-based screening at departure, transit and arrival airports to streamline the checkpoint journey to make it even safer and more efficient.”

“Biometrics is an urgently needed solution to provide seamless checkpoint security,” said Global Market Director Aviation, Richard Thompson . “Ever increasing air passenger traffic plus advances in biometrics, artificial intelligence and integrated screening technology mean that risk-based screening is now firmly on the fast track. We look forward to offering a preview of the checkpoint solution of the future to delegates at inter airport Europe 2019.”

Enquiries:

If you would like to speak with someone regarding this press release and/or preview this checkpoint solution, Smiths Detection will be presenting at Stand 410, Hall B6 at inter airport Europe.

References and data points:

  • At the beginning of 2018, SITA, the airlines technology supplier, reported that 77% of airports and 71% of airlines were planning major programs or R&D in biometric ID management over the next five years.
  • Airlines are responding to demands from passengers as 57% of passengers would "definitely use biometrics" if it helps them get quicker through the boarding process, according to SITA.
  • According to the IATA 2018 Passenger Survey , 45% of air travellers choose biometric identification as a replacement of their passport.
  • Over 65 percent of passenger’s were inclined towards sharing additional personal information to speed up their processing at the airport. Speed and convenience are paramount, according to IATA .

Recent press releases:

###

About Smiths Detection

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information visit http://www.smithsdetection.com .

About inter airport Europe

From 8 – 11 October 2019, inter airport Europe 2019, the 22nd International Exhibition for Airport Equipment, Technology, Design and Services will take place at the Munich Trade Fair Centre in Germany.

For manufacturers and suppliers of airport equipment, technology, design and services, inter airport Europe provides the opportunity to meet specialists from airports, airlines, air cargo carriers as well as aviation support from all over the world looking to invest in future-oriented, modern solutions for the interconnected airport. The world’s leading airport exhibition is renowned for covering the most comprehensive range of products and services for the entire airport: technology and services for ground handling, airport equipment, terminal operations, airport IT solutions and airport design.

For more information visit https://www.interairporteurope.com/welcome#/


1 https://www.iata.org/pressroom/pr/Pages/2018-10-24-02.aspx

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye